A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2032-12-31
Target enrollment:
Participant gender:
Summary
This study is designed to compare the efficacy and safety of KN026 combined chemotherapy with or without Enlonstobart versus Trastuzumab combined chemotherapy with or without Pembrolizumab as first-line treatment in HER2-positive unresectable locally advanced or metastatic gastric cancer.